Harry Bleiberg

13.7k total citations · 2 hit papers
163 papers, 10.2k citations indexed

About

Harry Bleiberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Harry Bleiberg has authored 163 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 62 papers in Pulmonary and Respiratory Medicine and 57 papers in Surgery. Recurrent topics in Harry Bleiberg's work include Colorectal Cancer Treatments and Studies (68 papers), Gastric Cancer Management and Outcomes (47 papers) and Cancer Treatment and Pharmacology (28 papers). Harry Bleiberg is often cited by papers focused on Colorectal Cancer Treatments and Studies (68 papers), Gastric Cancer Management and Outcomes (47 papers) and Cancer Treatment and Pharmacology (28 papers). Harry Bleiberg collaborates with scholars based in Belgium, France and Netherlands. Harry Bleiberg's co-authors include Eric Van Cutsem, David Cunningham, Yves Humblet, David Khayat, Salvatore Siena, M. Mueser, A. Harstrick, Armando Santoro, Chris Verslype and Ian Chau and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Harry Bleiberg

160 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 3.9k citations Harry Bleiberg, Eric Van Cutsem et al. profile →
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

1998 786 citations Philippe Rougier, Eric Van Cutsem et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harry Bleiberg Belgium	40	7.2k	4.2k	2.5k	1.7k	1.7k	163	10.2k
C. Boni Italy	34	11.0k 1.5×	5.5k 1.3×	3.3k 1.3×	1.7k 1.0×	1.7k 1.0×	122	13.9k
Jean A. Maroun Canada	35	7.4k 1.0×	2.6k 0.6×	2.1k 0.8×	1.4k 0.8×	1.4k 0.9×	136	9.6k
Alberto Sobrero Italy	45	9.6k 1.3×	3.9k 0.9×	2.0k 0.8×	2.7k 1.6×	1.7k 1.0×	207	12.1k
Jim Cassidy United Kingdom	42	9.4k 1.3×	3.1k 0.7×	2.3k 0.9×	2.4k 1.4×	1.5k 0.9×	122	11.7k
Bruno Landi France	26	5.9k 0.8×	2.9k 0.7×	1.7k 0.7×	1.5k 0.9×	1.5k 0.9×	70	8.3k
H. Cortés-Funes Spain	44	6.4k 0.9×	2.6k 0.6×	2.1k 0.8×	1.0k 0.6×	1.8k 1.1×	192	9.6k
Eduardo Díaz‐Rubio Spain	49	8.7k 1.2×	3.5k 0.8×	2.4k 1.0×	2.0k 1.2×	2.0k 1.2×	351	12.0k
Gunnar Folprecht Germany	37	8.6k 1.2×	3.6k 0.9×	2.2k 0.9×	3.1k 1.8×	1.4k 0.8×	198	10.7k
Niall C. Tebbutt Australia	48	9.3k 1.3×	4.4k 1.1×	3.0k 1.2×	1.7k 1.0×	2.7k 1.6×	255	12.8k
Fernando Rivera Spain	41	10.2k 1.4×	4.7k 1.1×	2.6k 1.0×	2.6k 1.5×	1.9k 1.2×	168	12.9k

Countries citing papers authored by Harry Bleiberg

Since Specialization

Citations

This map shows the geographic impact of Harry Bleiberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Bleiberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Bleiberg more than expected).

Fields of papers citing papers by Harry Bleiberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Bleiberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Bleiberg. The network helps show where Harry Bleiberg may publish in the future.

Co-authorship network of co-authors of Harry Bleiberg

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Bleiberg. A scholar is included among the top collaborators of Harry Bleiberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Bleiberg. Harry Bleiberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ouakrim, Driss Ait, Cécile Pizot, Matteo Malvezzi, et al.. (2015). Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ. 351. h4970–h4970. 172 indexed citations

Autier, Philippe, Driss Ait Ouakrim, Matteo Malvezzi, et al.. (2013). Trends in colorectal cancer mortality and screening activities in European countries. European Journal of Cancer. 49. 2 indexed citations

Braeckman, Johan, Philippe Autier, Christian Garbar, et al.. (2007). Computer‐aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. British Journal of Urology. 101(3). 293–298. 79 indexed citations

Bleiberg, Harry, Philippe Autier, Alain Hendlisz, et al.. (2006). Colorectal cancer (CRC) screening using sigmoidoscopy followed by colonoscopy: a feasibility and efficacy study on a cancer institute based population. Annals of Oncology. 17(8). 1328–1332. 8 indexed citations

Delaunoit, Thierry, Raphaël Maréchal, Alain Hendlisz, et al.. (2004). Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination. Anti-Cancer Drugs. 15(7). 725–728. 2 indexed citations

Bleiberg, Harry. (2002). Hemoccult should no longer be used for the screening of colorectal cancer. Annals of Oncology. 13(1). 44–46. 17 indexed citations

Buecher, Bruno & Harry Bleiberg. (2001). Non‐systemic chemotherapy in the treatment of colorectal cancer—portal vein, hepatic arterial and intraperitoneal approaches. Alimentary Pharmacology & Therapeutics. 15(10). 1527–1541. 4 indexed citations

Awada, Ahmad, Pierre Bourgeois, Nathalie Cornez, et al.. (1999). A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors. Clinical Cancer Research. 3833. 1 indexed citations

Brienza, S., M.A. Bensmaïne, P Soulié, et al.. (1999). Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program. Annals of Oncology. 10(11). 1311–1316. 45 indexed citations

10.

Rougier, Philippe, Eric Van Cutsem, Emilio Bajetta, et al.. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet. 352(9138). 1407–1412. 786 indexed citations breakdown →

11.

Bleiberg, Harry, Frank Hulstaert, Marc Buyse, & P de Keyser. (1998). Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy. Anti-Cancer Drugs. 9(9). 773–777. 6 indexed citations

12.

Tueni, Elias, A. Van Oosterom, Ad Backx, et al.. (1997). Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. British Journal of Cancer. 76(10). 1376–1381. 16 indexed citations

13.

Pottelsberghe, C van, T.C. Kok, B Paillot, et al.. (1996). Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European organization for research and treatment of cancer, gastrointestinal tract cancer cooperative group). European Journal of Cancer. 32(8). 1432–1433. 2 indexed citations

14.

Bleiberg, Harry, et al.. (1994). Cost-effectiveness analysis of antiemetic treatment. Supportive Care in Cancer. 2(3). 145–149. 4 indexed citations

15.

Ravoet, Christophe, Martine Piccart, Dominique Bron, et al.. (1992). A phase I clinical trial of recombinant human interleukine-6 (rhIL-6) in solid tumors. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 232. 1 indexed citations

16.

Bleiberg, Harry, B. Gérard, & Philippe Deguiral. (1992). Adjuvant therapy in resectable gastric cancer. British Journal of Cancer. 66(6). 987–991. 17 indexed citations

17.

Bleiberg, Harry, et al.. (1992). A phase I trial of a new antiemetic drug—clebopride malate—in cisplatin-treated patients. Annals of Oncology. 3(2). 141–143. 6 indexed citations

18.

Nicaise, Charles, et al.. (1983). Étude en phase i de l'alizapride chez des patients cancéreux traites au cisplatine. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 59(31). 2161–2165. 4 indexed citations

19.

Osteaux, Michel, et al.. (1977). [Contribution of computerized axial tomography in hepatic tumor pathology. 1st experiences].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 6(4). 207–8. 1 indexed citations

20.

Bleiberg, Harry, et al.. (1971). [Autoradiographic measurement of cell proliferation at different levels of the normal and pathologic gastrointestinal tract. Use of biopsies incubated in vitro].. PubMed. 16(3). 233–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact